As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
37 Analysts have issued a AbbVie forecast:
37 Analysts have issued a AbbVie forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 59,644 59,644 |
7%
7%
|
|
| Gross Profit | 42,443 42,443 |
14%
14%
|
|
| EBITDA | 27,967 27,967 |
17%
17%
|
|
| EBIT (Operating Income) EBIT | 19,713 19,713 |
27%
27%
|
|
| Net Profit | 2,348 2,348 |
54%
54%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
| Head office | United States |
| CEO | Robert Michael |
| Employees | 55,000 |
| Founded | 2011 |
| Website | www.abbvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


